Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-11-28

FDA Approved: OXALIPLATIN — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental application for oxaliplatin submitted by Sandoz Inc., approving a generic version of the chemotherapy drug. The approval is under th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OXALIPLATIN (Oxaliplatin)

Snippet

SUPPL AP for OXALIPLATIN (OXALIPLATIN)